Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Scopolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.98 |
| ▸ | TSHR | P16473 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 4/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.93 |
| ▸ | TP53 | P04637 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scopolamine SCHEMBL219721 | 1.00 | KMT2A (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL219719 | 1.00 | KMT2A (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL9297496 | 0.99 | BLM (0.98) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL4966132 | 0.99 | CHRM1 (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL20754076 | 0.99 | CHRM1 (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL23371689 | 0.99 | CHRM1 (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL18603971 | 0.99 | CHRM1 (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL24175406 | 0.99 | CHRM1 (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL22393238 | 0.99 | CHRM1 (1.00) | KMT2ACHRM1CHRM4TSHRLMNA | |
| Scopolamine SCHEMBL24751820 | 0.99 | CHRM1 (1.00) | KMT2ACHRM1CHRM4TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116731007-B | Preparation method of scopolamine hydrobromide | 成都第一制药有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-116731007-A | Preparation method of scopolamine hydrobromide | 成都第一制药有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2017-05-04 | — | — | US | claimed |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2015-12-10 | — | — | US | claimed |
| US-20130230571-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2013-09-05 | — | — | US | claimed |
| EP-2624834-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2013-08-14 | — | — | EP | claimed |
| EP-1480677-B8 | COMPOSITION FOR STABILIZING HYALURONIC ACID | CARL ZEISS MEDITEC SAS (FR) | 2012-05-23 | — | — | EP | claimed |
| WO-2012047813-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| WO-2012033956-A1 | COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-03-15 | — | — | WO | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0083373-A4 | MOTION SICKNESS SPRAY COMPOSITION AND METHOD. | KEY PHARMA (US) | 1985-02-28 | — | — | EP | claimed |
| EP-0083373-A1 | MOTION SICKNESS SPRAY COMPOSITION AND METHOD | Key Pharmaceuticals, Inc. (US) | 1983-07-13 | — | — | EP | claimed |
| WO-1983000286-A1 | MOTION SICKNESS SPRAY COMPOSITION AND METHOD | KEY PHARMA (US) | 1983-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | CHRM1 2/4885KMT2A 2800/4885CHRM4 5/4885 |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | CHRM1 2/4885KMT2A 2131/4885CHRM4 4/4885 |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | CHRM1 2/4885KMT2A 2126/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.